Literature DB >> 24722448

Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD.

Ko-Lin Kuo1, Szu-Chun Hung2, Tzong-Shyuan Lee3, Der-Cherng Tarng4.   

Abstract

High-dose intravenous iron supplementation is associated with adverse cardiovascular outcomes in patients with CKD, but the underlying mechanism is unknown. Our study investigated the causative role of iron sucrose in leukocyte-endothelium interactions, an index of early atherogenesis, and subsequent atherosclerosis in the mouse remnant kidney model. We found that expression levels of intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and adhesion of U937 cells increased in iron-treated human aortic endothelial cells through upregulated NADPH oxidase (NOx) and NF-κB signaling. We then measured mononuclear-endothelial adhesion and atherosclerotic lesions of the proximal aorta in male C57BL/6 mice with subtotal nephrectomy, male apolipoprotein E-deficient (ApoE(-/-)) mice with uninephrectomy, and sham-operated mice subjected to saline or parenteral iron loading. Iron sucrose significantly increased tissue superoxide production, expression of tissue cell adhesion molecules, and endothelial adhesiveness in mice with subtotal nephrectomy. Moreover, iron sucrose exacerbated atherosclerosis in the aorta of ApoE(-/-) mice with uninephrectomy. In patients with CKD, intravenous iron sucrose increased circulating mononuclear superoxide production, expression of soluble adhesion molecules, and mononuclear-endothelial adhesion compared with healthy subjects or untreated patients. In summary, iron sucrose aggravated endothelial dysfunction through NOx/NF-κB/CAM signaling, increased mononuclear-endothelial adhesion, and exacerbated atherosclerosis in mice with remnant kidneys. These results suggest a novel causative role for therapeutic iron in cardiovascular complications in patients with CKD.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722448      PMCID: PMC4214520          DOI: 10.1681/ASN.2013080838

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  48 in total

1.  Out, damned dot: studies of the NADPH oxidase in atherosclerosis.

Authors:  K K Griendling; D G Harrison
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  Activity of neutrophil NADPH oxidase in iron-deficient anemia.

Authors:  Erdal Kurtoglu; Aysegul Ugur; Abdulkerim Kasim Baltaci; Rasim Mogolkoc; Levent Undar
Journal:  Biol Trace Elem Res       Date:  2003       Impact factor: 3.738

3.  Iron overload diminishes atherosclerosis in apoE-deficient mice.

Authors:  E A Kirk; J W Heinecke; R C LeBoeuf
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

4.  De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion.

Authors:  Chiang-Ting Chien; Po-Huang Lee; Chau-Fong Chen; Ming-Chieh Ma; Ming-Kuen Lai; Su-Ming Hsu
Journal:  J Am Soc Nephrol       Date:  2001-05       Impact factor: 10.121

5.  Magnolol attenuates VCAM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits.

Authors:  Yung-Hsiang Chen; Shing-Jong Lin; Jaw-Wen Chen; Hung-Hai Ku; Yuh-Lien Chen
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

6.  Oxidative damage to DNA constituents by iron-mediated fenton reactions. The deoxyguanosine family.

Authors:  E S Henle; Y Luo; W Gassmann; S Linn
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

7.  Iron administration and clinical outcomes in hemodialysis patients.

Authors:  Harold I Feldman; Jill Santanna; Wensheng Guo; Howard Furst; Eunice Franklin; Marshall Joffe; Sue Marcus; Gerald Faich
Journal:  J Am Soc Nephrol       Date:  2002-03       Impact factor: 10.121

8.  The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure.

Authors:  Chun Soo Lim; Nosratola D Vaziri
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

9.  Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper.

Authors:  Nadina Stadler; Robyn A Lindner; Michael J Davies
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-03-04       Impact factor: 8.311

10.  Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice.

Authors:  Susanne Bro; Flemming Moeller; Claus B Andersen; Klaus Olgaard; Lars B Nielsen
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

View more
  32 in total

1.  HFE p.C282Y gene variant is associated with varicose veins in Russian population.

Authors:  Ekaterina A Sokolova; Alexandra S Shadrina; Kseniya S Sevost'ianova; Andrey I Shevela; Evgenii Yu Soldatsky; Evgenii I Seliverstov; Marina Yu Demekhova; Oleg A Shonov; Evgenii A Ilyukhin; Mariya A Smetanina; Elena N Voronina; Igor A Zolotukhin; Maxim L Filipenko
Journal:  Clin Exp Med       Date:  2015-09-28       Impact factor: 3.984

Review 2.  The Labile Side of Iron Supplementation in CKD.

Authors:  Itzchak Slotki; Zvi Ioav Cabantchik
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

Review 3.  Overview of iron metabolism in health and disease.

Authors:  Som Dev; Jodie L Babitt
Journal:  Hemodial Int       Date:  2017-03-15       Impact factor: 1.812

Review 4.  Oxidative stress in chronic kidney disease.

Authors:  Kristien Daenen; Asmin Andries; Djalila Mekahli; Ann Van Schepdael; François Jouret; Bert Bammens
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

5.  Intravenous Iron Therapy in Heart Failure With Reduced Ejection Fraction: Tackling the Deficiency.

Authors:  Konrad Teodor Sawicki; Hossein Ardehali
Journal:  Circulation       Date:  2021-07-26       Impact factor: 39.918

6.  A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.

Authors:  Sunil Bhandari; Philip A Kalra; Jatin Kothari; Patrice M Ambühl; Jeppe H Christensen; Ashot M Essaian; Lars L Thomsen; Iain C Macdougall; Daniel W Coyne
Journal:  Nephrol Dial Transplant       Date:  2015-04-28       Impact factor: 5.992

Review 7.  Safety concerns about intravenous iron therapy in patients with chronic kidney disease.

Authors:  Lucia Del Vecchio; Selena Longhi; Francesco Locatelli
Journal:  Clin Kidney J       Date:  2016-01-06

8.  MMP-9 Deletion Attenuates Arteriovenous Fistula Neointima through Reduced Perioperative Vascular Inflammation.

Authors:  Yu-Chung Shih; Po-Yuan Chen; Tai-Ming Ko; Po-Hsun Huang; Hsu Ma; Der-Cherng Tarng
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

Review 9.  Intravenous iron therapy and the cardiovascular system: risks and benefits.

Authors:  Lucia Del Vecchio; Robert Ekart; Charles J Ferro; Jolanta Malyszko; Patrick B Mark; Alberto Ortiz; Pantelis Sarafidis; Jose M Valdivielso; Francesca Mallamaci
Journal:  Clin Kidney J       Date:  2020-11-26

10.  Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.

Authors:  Lisa H Fell; Sarah Seiler-Mußler; Alexander B Sellier; Björn Rotter; Peter Winter; Martina Sester; Danilo Fliser; Gunnar H Heine; Adam M Zawada
Journal:  Nephrol Dial Transplant       Date:  2016-03-24       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.